Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Small-Cell Lung Carcinoma: early-phase trial registry
6 of 32 indexed Non-Small-Cell Lung Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #477 of 28,707 conditions by registered trial count.
32 US clinical trials · 6 currently recruiting · #477 of 28,707 conditions by registered trial count
Non-Small-Cell Lung Carcinoma: 32 US clinical trials tracked, 6 recruiting.
Non-Small-Cell Lung Carcinoma is the subject of 32 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 3 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-carcinoma
OPEN 6 | RECR 19% | LATE 5 | EARLY 23 | RANK #477 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Allergy (19% recruiting · 16 trials)
Non-Small-Cell Lung Carcinoma lists 6 open slots (19% of 32 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Small-Cell Lung Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Small-Cell Lung Carcinoma is recruiting below its size-band peers.
6 of 32 indexed trials (18.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Small-Cell Lung Carcinoma trials is spread across many organizations.
Pfizer accounts for 3 of 32 trials (9.4%). 28 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-Small-Cell Lung Carcinoma enrolment sits around 118 participants.
Median target enrolment is 118 among the 31 trials that report a genuine target (sentinel values excluded). 14 of those (45.2%) plan for fewer than 100 participants.
-
Non-Small-Cell Lung Carcinoma research is mostly interventional.
30 interventional and 2 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
32 total, page 1 of 1
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
VastBiome
NCT05037825
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Pfizer
NCT07144280
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
NCT06772623
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
AstraZeneca
NCT04995523
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium
NCT07284186
Retifanlimab and Ruxolitinib In Solid Malignancies
University of California, San Diego
NCT07219576
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
Daiichi Sankyo
NCT04042701
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NeoImmuneTech
NCT04984811
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT05358249
Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment
M.D. Anderson Cancer Center
NCT03731585
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
Joseph J. Cullen, MD, FACS
NCT02905591
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
NCT02432963
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Roswell Park Cancer Institute
NCT03678350
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme
NCT04738487
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
Celgene
NCT00540514
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Telik
NCT00080340
Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence
M.D. Anderson Cancer Center
NCT00915005
Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2
Instituto Nacional de Cancer, Brazil
NCT01836575
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Pfizer
NCT04351334
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor
NCT03517488
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
Syndax Pharmaceuticals
NCT00602030
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Hoffmann-La Roche
NCT01801111
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
MedImmune
NCT00081315
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Pfizer
NCT00600821
Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
NCT00124280
Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
Dana-Farber Cancer Institute
NCT00137800
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
Eli Lilly and Company
NCT00105092
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
Pharmacyclics
NCT00102505
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Rahul Aggarwal
NCT03590054
Neoadjuvant Pembrolizumab
Neal Ready MD PhD
NCT02818920
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Wake Forest University Health Sciences
NCT01185639
Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Genzyme, a Sanofi Company
NCT00078455
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 10 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Small-Cell Lung Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Small-Cell Lung Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Small-Cell Lung Carcinoma page
32 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Non-Small-Cell Lung Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Non-Small-Cell Lung Carcinoma trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Small-Cell Lung Carcinoma condition card totals 32 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.